Roche scraps 2 Huntington’s studies, handing Ionis more bad news

Trial StartnegativeNegative

AI Analysis

Summary

Roche has discontinued two Huntington's disease studies partnered with Ionis, compounding recent setbacks for Ionis which also experienced a late-stage failure in an ATTR-CM program.

Outcome Details

Roche discontinued two Huntington's disease studies partnered with Ionis; Ionis also experienced a late-stage failure in ATTR-CM

Importance:7/10

Sentiment:

-0.90

trial discontinuationpartnershipHuntington's diseaseATTR-CMlate-stage failure

Related Companies

$RHHBY $IONS

Read the original article

Published by BioSpace on July 10, 2026 11:59 AM

Read Original